adcetris
(brentuximab vedotin)SEAGEN INC.
Usage: ADCETRIS is indicated for treating adult and pediatric patients with previously untreated or relapsed classical Hodgkin lymphoma (cHL) and systemic anaplastic large cell lymphoma (sALCL), as well as for consolidation post-transplant in high-risk cHL. It is used in combination with specific chemotherapy regimens.